Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JANX008 · 1 trial · 7 indications
| Arm | Type | Description |
|---|---|---|
| Dose Escalation | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Dosage per cohort will increase to determine the maximum tolerable dose. |
| Backfill Expansion | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at levels previously declared tolerable. |
| Expansion | EXPERIMENTAL | Subjects will be dosed weekly during each 21-day cycle. Subjects will be dosed at the preliminary recommended Phase 2 dose (RP2D). |
| Name | Type | Description |
|---|---|---|
| JANX008 | DRUG | JANX008 is dosed via IV weekly in a 21-day cycle |
Inclusion Criteria: * Subjects ≥18 years of age at the time of signing informed consent * Histologically or cytologically documented locally advanced or metastatic NSCLC, SCCHN, CRC, RCC, SCLC, PDAC, TNBC * Progressed or was intolerant to all available therapies known to confer clinical benefit app...
Top 20 of 90 competitors
JANX008 is an investigational small molecule being developed for the treatment of Non-Small Cell Lung Cancer. It is currently in Phase 1 clinical development and is being studied in patients with advanced or metastatic solid tumor malignancies, including Non-Small Cell Lung Cancer.
JANX008 targets EGFR, the epidermal growth factor receptor. By targeting EGFR, JANX008 is designed to interfere with signaling pathways that can drive tumor growth in certain cancers, including Non-Small Cell Lung Cancer.
JANX008 is being developed by Janux Therapeutics, Inc., a biopharmaceutical company. Janux Therapeutics is listed on the stock exchange under the ticker symbol JANX.
JANX008 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The Phase 1 trial is active but not recruiting participants.
JANX008 is being evaluated in a Phase 1 clinical trial with the identifier NCT05783622. This trial is studying JANX008 in subjects with advanced or metastatic solid tumor malignancies, including Non-Small Cell Lung Cancer, and is being conducted in the United States.
JANX008 is the drug name used in clinical development. No alternative names have been established for this investigational agent. It is being studied under the name JANX008 in clinical trials.